Wake Forest School of Medicine, Winston-Salem, NC, USA.
Division of Infectious Diseases, Department of Internal Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Diagn Microbiol Infect Dis. 2021 Oct;101(2):115453. doi: 10.1016/j.diagmicrobio.2021.115453. Epub 2021 Jun 12.
Injection drug use (IDU) is a risk factor for infective endocarditis (IE) and hepatitis C virus (HCV) infection. This retrospective cohort study assessed HCV's impact on outcomes of adult people who inject drugs (PWID). Those admitted due to IE using modified Duke criteria from January 2012 through May 2018 were identified. The cohort was divided into HCV seropositive and seronegative groups. The seropositive group was further stratified according to HCV viremia. Complications and mortality during the IE hospitalization, at 10 weeks, and 1 year were compared across groups. Clinical factors were similar between the cohorts, except patients without viremia (29, 81%) required more ICU admissions than with viremia (30, 60%) (P < 0.05). There was no difference in mortality at all time periods between the groups. Although several factors affect mortality in PWID with IE, neither HCV antibody positivity nor viremia appear to increase the risk for complications or death.
注射吸毒（IDU）是感染性心内膜炎（IE）和丙型肝炎病毒（HCV）感染的危险因素。这项回顾性队列研究评估了 HCV 对成年 IDU 患者结局的影响。根据 2012 年 1 月至 2018 年 5 月修正后的 Duke 标准，确定了因 IE 入院的患者。将队列分为 HCV 血清阳性和血清阴性组。根据 HCV 病毒血症，血清阳性组进一步分层。比较了各组 IE 住院期间、10 周和 1 年的并发症和死亡率。除了无病毒血症的患者（29 例，81%）比有病毒血症的患者（30 例，60%）需要更多的 ICU 入院（P < 0.05）外，两组之间的临床因素相似。在所有时间段，两组之间的死亡率均无差异。尽管有几个因素会影响 IE 合并 IDU 的死亡率，但 HCV 抗体阳性或病毒血症似乎不会增加并发症或死亡的风险。
